The FDA rejected Merck & Co.'s glaucoma medicine tafluprost, which is also known by its brand name Saflutan and is already available in some overseas markets, according to a Reuter's report.
Merck did not issue a release or note the FDA's reasoning behind the rejection, but included a brief mention in the company's regulatory filing with the Securities and Exchange Commission, the report said,
Related Articles on Ophthalmology:
Study: Patients With Glaucoma Vision Loss Have Higher Fall Risk
Ophthalmologist on the Move: Dr. Rodney P. Coe Joins the Retina Group of New York
10 Points on Ophthalmology in Surgery Centers
Merck did not issue a release or note the FDA's reasoning behind the rejection, but included a brief mention in the company's regulatory filing with the Securities and Exchange Commission, the report said,
Related Articles on Ophthalmology:
Study: Patients With Glaucoma Vision Loss Have Higher Fall Risk
Ophthalmologist on the Move: Dr. Rodney P. Coe Joins the Retina Group of New York
10 Points on Ophthalmology in Surgery Centers